Biopharmaceutical company Hoth Therapeutics announced that its innovative therapy HT-001 has received approval from Spanish regulatory authorities to conduct a Phase 2a clinical trial.

This European authorization marks an important milestone in the development of the drug. The latest interim data disclosed shows that HT-001 demonstrates encouraging therapeutic effects in cancer patients. Preliminary trial results have confirmed the potential of this therapy in controlling tumor progression and improving patients’ clinical symptoms. Receiving recognition from the Spanish drug regulatory authorities provides a solid foundation for Hoth Therapeutics to further advance clinical research in the European market. The company plans to optimize subsequent trial protocols based on existing data and accelerate the global development of HT-001.